Purpose. The aim of this study was to assess the biotope of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast, and clarify the possible epidemiological relationship between environmental and clinical strains.
INTRODUCTION
Cryptococcosis is mostly diagnosed among immunodeficient individuals, with 223 000 cases occurring annually worldwide [1] . The yearly death rate related to this fungal infection is estimated at 181 000 cases, of which 90 % are registered in sub-Saharan Africa [2] . The pathogen responsible is an encapsulated yeast belonging to the Cryptococcus neoformans/Cryptococcus gattii species complex [3] , which has a global distribution. Cryptococcus causes infections mostly in immunocompromised individuals. Yeast from the C. gattii complex leads to more infections in immunocompetent patients than C. neoformans [4] . C. gattii infection, alongside lung lesions, usually leads to a high ratio of central nervous system infections and complications, including cryptococcomas [4] , whereas Cryptococcus deuterogattii infection more commonly leads to pulmonary disease [5] . The C. gattii complex has been described as less sensitive to antifungal therapy than the C. neoformans species complex; therefore, more aggressive interventions are usually required for treatment of C. gattii species complex infections [6] . The taxonomy has been recently revised due to the differences between both species in terms of the intergenic spacer sequences (IGS) of the ribosomal DNA [7, 8] , physiological and biochemical characteristics [8, 9] , mass spectra generated by matrix-assisted laser desorption ionization-time of flight MS (MALDI-TOF MS) profiles [8, 10] geographical distribution and habitat [8, 11] ), antifungal-susceptibility profiles [6, 8, 12, 13] , pathophysiology [8, 14] , and clinical manifestations [8, 15] . In the C. neoformans subgroup, C. neoformans variety grubii (serotype A, genotype AFLP1/VNI, AFLP1A/VNB/VNII and AFLP1B/ VNII) has been renamed as C. neoformans, which is the major cause of cryptococcal disease. C. neoformans var. neoformans (serotype D, genotype AFLP2/VNIV) has been renamed as Cryptococcus deneoformans. In the C. gattii species complex, five distinct species are recognized, including C. gattii (genotype AFLP4/VGI), Cryptococcus bacillisporus (genotype AFLP5/VGIII), C. deuterogattii (genotype AFLP6/VGII), Cryptococcus tetragattii (genotype AFLP7/VGIV) and Cryptococcus decagattii (AFLP10/ VGIV) [3] . Cryptococcal meningitis (CM) is still an opportunistic and one of the most common central nervous system infections, particularly in developing countries, despite the use of antiretroviral therapy (ART). The infection is acquired through exposure to environmental Cryptococcus by inhaling spores or dehydrated yeasts, which can penetrate the pulmonary alveoli [16, 17] .
Studies conducted worldwide have examined the clinical and epidemiological aspects of this complex, and only four studies in Botswana, Cuba, Brazil and Kenya have compared the molecular epidemiology of clinical and environmental strains [18] [19] [20] [21] . They described significant differences in the genetic compositions of clinical and environmental populations in these areas. To date, no studies have examined the genetic diversity between environmental and clinical strains of the C. gattii/C. neoformans species complex in subSaharan Africa, and especially in Ivory Coast. The main objective of this study was to compare the genotypes of environmental and clinical strains of the C. gattii/C. neoformans species complex, and their susceptibility to antifungal drugs to understand the origin of contamination of patients in Abidjan, Ivory Coast.
METHODS

Patients and clinical strains
This prospective study was performed in the Infectious and Tropical Diseases Unit (Service des Maladies Infectieuses et Tropicales, SMIT), at the teaching hospital of Treichville, Abidjan, Ivory Coast, between May 2014 and September 2015. We reviewed the files of 36 patients with a suspected CM. Patients with negative blood tests for human immunodeficiency virus (HIV), as well as those without documented blood test results, were excluded. CM was confirmed by identification of Cryptococcus in CSF (cerebrospinal fluid) using direct examination with China ink, by detection of the cryptococcal antigen in CSF and by positive culture on Sabouraud medium. The identification of each strain after culturing was performed via a positive urea-indole test and the commercial identification kit ID32C (bioM erieux). Among the 36 patients evaluated, we eventually included 10 HIVpositive patients with confirmed CM. The CSF of each patient was cultured on Sabouraud-chloramphenicol, and five isolates of Cryptococcus per patient were recovered, as previously described [22] .
Phenotypic characterization of the Cryptococcus species was achieved by chemotyping in L-canavanine-glycine-bromothymol blue (CGB) agar. CGB agar was used to differentiate C. neoformans complex species and C. gattii complex species, as described previously. The blue colour of glycine assimilation on CGB agar indicated a positive reaction caused by the C. gattii species complex, whereas the C. neoformans species complex did not cause a colour change [23] .
Demographic, clinical, biological and therapeutic data were collected using a structured questionnaire. None of the 10 patients received systemic antifungal treatment prior to the study, and data were obtained regarding the patient's district of origin.
Environmental strains
Six hundred and sixty-seven environmental samples were collected from 136 Eucalyptus camaldulensis trees and 13 Mangifera indica trees, as well as 518 pigeon-dropping samples from different sites in the vicinity of the living environments of the patients. The sites chosen included the eight major districts of Abidjan, the economic capital city located in the south-east of the country (Fig. 1) . A minimum of 32 and a maximum of 185 samples were collected at each site, as shown in Table 1 .
Collection, isolation and identification of environmental Cryptococcus strains Samples were collected by rubbing the inside of the hollows or fissures of trees with a sterile cotton-tipped swab moistened in a solution of sterile distilled water supplemented with chloramphenicol (10 mg ml À1 ). The swab was placed into a tube with 3 ml of the solution, and the tube was shaken for 5 min without removing the swab. Then, the swab was removed and the suspension was left to sediment for at least 10 min. A total of 10 µl supernatant was inoculated on Niger seed agar containing chloramphenicol and biphenyl at concentrations of 0.5 g l À1 and 100 mg l À1 , respectively, in a Petri dish. The plates were incubated for 14 days at 37 C, but were monitored daily starting from day 2 to observe the appearance of brown pigmented colonies. All brown-coloured colonies grown on the plates were isolated on a fresh Niger seed agar plate to collect pure single colonies. Isolates were then examined by microscopy to assess the yeast morphology and capsule presence, and tested for urease activity and the ability to cause a change of colour on CGB [23] .
Antifungal-susceptibility testing
The in vitro susceptibility profile of Cryptococcus species against antifungal agents was determined using the reference broth microdilution method in accordance with document M27-A3 of the Clinical and Laboratory Standards Institute (CLSI) [24] . The final antifungal concentrations ranged from 0.125 to 16 µg ml À1 for amphotericin B, and from 0.25 to 64 µg ml À1 for fluconazole and flucytosine.
The MICs for fluconazole and flucytosine were defined as concentrations causing a 50 % reduction in turbidity compared to the growth of the control at 72 h. For amphotericin B, the MIC was defined as the concentration resulting in 100 % inhibition relative to the growth of the control. Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were used as control strains [24] . For the C. neoformans and C. gattii species complex, no break-point information is available to follow, and in this case, we used epidemiological cut-off values to discriminate wild-type strains from mutants with reduced susceptibility to antifungals drugs [12, 13, 25] .
Molecular analysis
To determine the molecular type, genomic DNA was extracted, as previously described [26] . Four primers designed for cloning LAC1 and a pair of primers for CAP64 [27] (Table 2) were used in a slightly modified method, as previously described [26, 28] . The following reference strains were used for each experiment: WM148 (=CBS10085=ATCC MYA-4564, VNI, serotype A); WM626 (=CBS10084=ATCC MYA-4565, VNII, serotype A); WM628 (=CBS10080=ATCC MYA4566, VNIII, serotype [29] .
Primers for the minisatellite-specific core sequence of the wild-type phage M13 and the microsatellite-specific sequences (GTG) 5 and (GACA) 4 were used as single PCR primers, as described elsewhere (Table 2 ) [29] . Amplifications were performed based on the primers used, as described previously [26, 28] . Briefly, for (GACA) 4 : initial denaturation was at 94 C for 3 min; followed by 40 cycles of denaturation (94 C, 30 s), annealing (40 C, 1 min) and extension (72 C, 1.5 min); and a final extension at 72 C for 7 min. M13 and (GTG) 5 underwent: initial denaturation at 94 C for 3 min; 40 cycles of denaturation (94 C, 30 s), annealing (50 C, 1 min) and extension (72 C, 1.5 min); and a final extension step at 72 C for 6 min. Amplification products were separated using electrophoresis in a 6 % Poly (NAT) Wide Mini S-2Â25 gel (Elchrom Scientific) in 1ÂTris acetate/EDTA buffer at 10 V cm À1 for 105 min. The bands were then visualized under UV light. A 100 bp molecular size marker (Promega) was loaded in each gel as a marker ladder. Migration patterns were captured with an Ingenius LR apparatus (Syngene), analysed with GeneSnap and Genetool software (Syngene), and integrated in a database using GeneDirectory software (http://www.syngene.com/genedirectory-2/; Syngene).
PCR-RFLP analyses were also performed using the URA5 and SJ01 primers ( Table 2 ). The reaction conditions were as follows: initial denaturation (94 C, 2 min); 35 cycles of denaturation (94 C, 45 s), annealing (61 C, 1 min) and extension (72 C, 2 min); and a final extension cycle at 72 C for 10 min.
Ten microlitres of each PCR product was double digested using Sau96I (15 U) and Hhal (15 U) for 5 h at 37 C, and the digested fragments were visualized on 1.5 % agarose gels stained with ethidium bromide. Migration patterns were captured with an Ingenius LR apparatus (Syngene). Molecular profiles obtained via PCR fingerprinting were analysed based on the presence or absence of readily apparent and well-defined bands in the digitized gel images with GeneSnap and Genetool software (Syngene), and integrated in a database using GeneDirectory software (Syngene; http:// www.syngene.com/genedirectory-2/).
Genotype comparisons
To compare the genotype profiles within our sample pool, a dendrogram comprising all strains of serotype A (n=12/12 for the environmental strains and n=32/50 for the clinical strains) was generated. We used the GeneDirectory software multi-experiment tool and included all profiles [(GACA) 4 , (GTG) 5 , M13 and URA5]. Comparisons were performed using the band-matching approach, with a percentage tolerance of 10 %, the unweighted pair group method with arithmetic mean (UPGMA) algorithm and the similarity coefficient of Dice.
RESULTS
Patients
Ten patients with CM were studied; the subjects included 50 % (5/10) women and 50 % (5/10) men, aged between 23 and 60 years, with a mean age of 41.8±12.2 years. All the patients were infected with HIV 1 with severe immunodepression (median CD4 counts of 82.6±111.3 cells µl À1 ), indicating an advanced stage of HIV infection. Table 3 summarizes the in vitro susceptibility data for fluconazole, flucytosine and amphotericin B obtained from the 50 clinical and 12 environmental strains using the broth microdilution method, according to the CLSI M27-A3 protocol, 2008 [24] . All isolates had a MIC 8 µg ml À1 to fluconazole and flucytosine, and hence a wild-type phenotype (Table 3) . Similarly, the in vitro activity of amphotericin B was uniform, with a MIC of 0.5-1 µg ml À1 for all species. We calculated the geometric mean for environmental and clinical strains for each antifungal drug. For the Table 2 . Primers used for molecular typing [27, 28] Serotyping/genotyping Primer name and sequence 
Antifungal-susceptibility testing
Serotyping LAC1-F-1 5¢-GGAACAGCAACCACACTACTG-3¢ LAC1-R-1 5¢-CATATTGGGTGGCATCTTACTGAGGGA-3¢ LAC1-F-2 5¢-CCAGGGAACATGTTGTTGAC-3¢ LAC1-R-2 5¢-GTTGTGGAAGGCAAAGAAAC-3¢ CAP64-F-1 5¢-GCCAAGGGAGTCTTATATGG-3¢ CAP64-R-2 5¢-GCAAAGGGTTCACCAAATCG-3¢ Genotyping URA5-1 5¢-ATGTCCTCCCAAGCCCTCGACTCCG-3¢ SJ01 5¢-TTAAGACCTCTGAACACCGTACTC-3¢ (GACA) 4 5¢-GACAGACAGACAGACA-3¢ (GTG) 5 5¢-GTGGTGGTGGTGGTG-3¢ M13 5¢-GAGGGTGGCGGTTCT-3¢
Genotyping of environmental and clinical strains
All positive samples were recovered from pigeon droppings (12/518; 2.3 % positive rate), whereas no positive strains were collected from trees. These samples were only found in one district, Adjam e, which is located in the centre of the city of Abidjan. Among the 50 clinical isolates, the overall serotype distribution was as follows: 32 were C. neoformans (serotype A, genotype AFLP1/VNI) collected from 8 patients, 13 were C. neoformans/C. deneoformans hybrids (AD, AFLP3/VNIII) collected from 3 patients, and 5 were C. deuterogattii (B, AFLP6/VGII) collected from 1 patient. It is noteworthy that two patients showed a mixed infection, each with four hybrids AD samples and one C. neoformans (A, AFLP1/VNI) sample.
Genotyping comparison between environmental and clinical strains
We compared the genetic profiles of 32 clinical isolates from eight patients to 12 environmental isolates. All environmental isolates were identified as C. neoformans (A, AFLP1/VNI). To generate a dendrogram (Fig. 2) , we excluded 18 samples (13 hybrids AD AFLP3/VNIII and 5 C. deuterogattii (B, AFLP6/VGII) from the 32 clinical isolates as they were different from serotype A strains.
The dendrogram (Fig. 2) shows 10 molecular subtypes (6 clusters and 4 isolated strains) among all the isolates when a value of >95 % similarity was used for the comparison. The 12 environmental strains grouped together in a single cluster, whereas the 14 clinical samples were dispersed between 5 clusters and 4 isolated strains.
The first clinical cluster (comprising patient strains 6.35-1 to -5 and 16218-1 to -3) was more similar to the environmental cluster (node at 92 %) than to other clinical strains (first node at 89 %, last node at 80 %). Additionally, clinical strains 16218-1, À2 and -3 were more closely related to the environmental cluster (node at 92 %) than to the other clinical strains 16218-4 and -5 isolated from the same patient (node at 88 %).
DISCUSSION
In vitro susceptibility tests are not routinely performed in Ivorian laboratories, particularly in the public-health services, even though these tests are extremely useful for selecting the appropriate therapy. In this study, we have reported that the MIC results obtained from clinical and environmental isolates showed that all strains, whatever their origin, were wild-type for the antifungal molecules tested. This might be attributed to the fact that most patients under study had no history of prior exposure to any of the antifungal agents. This result is consistent with previous findings of some investigators who found that antifungal susceptibility was not related to the clinical or environmental origin of the strains [30] . However, susceptibility profiles could depend on the species tested. C. gattii clinical strains from India or Brazil, respectively, showed more often a non-wild-type phenotype than C. neoformans strains when tested against fluconazole and ketoconazole [31] or fluconazole and itraconazole [32] . In the present study, we found, however, that none of our C. deuterogattii isolates had a mutant phenotype.
We reported here the predominance of C. neoformans (A, AFLP1/VNI) from clinical (32/50, 64 %) and environmental (12/12, 100 %) sources. Similar results have previously been observed in numerous studies conducted in other African geographical areas. For example, C. neoformans (A, AFLP1/ VN1) accounted for 91.4 and 77.4 % of the strains coming, Fig. 2 . Relationship between the genotypes obtained from the 32 clinical and the 12 environmental strains studied. Genotype data were generated by URA5 gene RFLP and microsatellite and minisatellite polymorphisms. The dendrogram obtained is based on UPGMA clustering using the UPGMA algorithm with a 10 % Dice correlation coefficient calculated from the profiles of 44 isolates of Cryptococcus. Each major group consists of strains with >95 % of similarity. The numbers 1 to 10 to the right of the dendrogram indicate the genetic subtypes (six clusters and four isolated strains). Bar, the percentage of similarity.
respectively, from clinical and from environmental sources in Kenya, and for 97 and 100 % of the strains coming, respectively, from clinical and environmental sources in Botswana [18, 33] . This genotype was predominant in immunocompromised patients and the high prevalence of AIDS in sub-Saharan Africa could explain its prevalence [22, 26, 28] .
Three patients had strains that were C. neoformans Â C. deneoformans hybrids (AD, AFLP3/VNIII). For the second time, we described the presence of this genotype in Ivory Coast [28] . The distribution of these hybrids is uneven worldwide. They often comprise a minority among clinical isolates, as shown in our previous study (11 %) . Other clinical studies carried out in Peru [34] , Denmark [35] and Serbia [36] showed, respectively, a prevalence of such samples of 3.1, 12 and 8.8 % only. However, these hybrid strains have a high prevalence (30 to 45 %) in Spain, Italy, Greece and Portugal [37] , and represented the majority (65 %) of samples recently isolated from patients in Seville, Spain [38] . The reasons for this discrepancy in distribution could be explained by the favourable bioclimatic conditions of these Mediterranean countries, better suited for the co-existence of the two C. neoformans varieties in the environment. This co-existence, in return, may allow hybridizations to occur at a higher rate. [39] . Among the three patients in our sudy, two had a mixed infection with both serotype A AFLP1/ VNI and serotype AD AFLP3/VNIII. Such mixed infections have been previously observed [26, 38, 40] . Finally, we had a patient with a C. deuterogattii (B, AFLP6/VGII) infection. This is also the second report of a human cryptococcosis due to C. deuterogattii in Ivory Coast, after the first depiction in a previous study [28, 41] . In Africa, the genotype (AFLP6/VGII) was only found so far in Ivory Coast, whereas it seems relatively common in others developing countries from Latin America and Asia [41] .
Concerning the environmental samples, the pigeon droppings yielded only C. neoformans (A, VNI) with a prevalence of 2.3 %. In fact, C. neoformans is prevalent worldwide in pigeon-dropping samples and has been reported in other African countries, such as Kenya (10 %), Libya (34 %), Egypt (18 %) Tunisia (10.4 %) and Nigeria 2016 (3 %) [18, [42] [43] [44] [45] .
No strains of Cryptococcus were recovered among 149 samples tested from two different species of trees. As reported by some authors, it is more difficult to obtain Cryptococcus from trees than from pigeon droppings [18, 42, 45] .
After comparisons of 32 clinical and 12 environmental serotype A AFLP1/VNI isolates, we generated 10 molecular subtypes. All of the environmental isolates were grouped in a single cluster, which showed very little genetic diversity. This lack of diversity for Cryptococcus from bird faeces was observed in previous studies, although with different methods, be it PCR fingerprinting or MSLT (Multilocus sequence Typing) [21, 46] . For example, using a selection of 9 microsatellite markers for high-resolution fingerprinting, IllnaitZaragozi et al. showed that a majority (70 %) of their environmental isolates clustered into a single microsatellite complex containing only a few clinical isolates (49 environmental versus 2 clinical isolates) [21] . In comparison, the clinical isolates in our study were much more diverse, with 32 isolates distributed into 5 clusters and 4 isolated strains. Clinical isolates also showed a strong genetic difference as two sets of clusters (cluster 2 and 3 versus cluster 4, 5 and 6) were separated by a similarity node at 80 %. This result confirms a finding that was observed in our previous studies in Western Africa in Cameroon [47] and Ivory Coast [26] . It is interesting to note that the eight clinical isolates grouped in cluster 2 were genetically more similar to the environmental isolates than to all the other clinical strains. This finding is consistent with previous studies suggesting that cryptococcosis can be acquired from exposure to pigeon droppings [48, 49] . Indeed, all of the environmental Cryptococcus strains were retrieved from only one of the eight districts investigated, i.e. Adjam e. This district is an important transit hub, with the most important bus station in the country and buses that serve all of Ivory Coast, as well as neighbouring countries. However, the clinical strains that had a genotype close to the environmental strains were not isolated from a patient living in Adjam e district, but from patients living in the Abobo district. It is a common practice in this district for households to have chicken or pigeon nests in the same house with humans. Therefore, the close proximity of chicken and pigeon cages to human habitation could be a significant risk factor for Cryptococcus infection, as described in Kenya [18] , and may explain our results. Furthermore, some patients had isolates with genetic profiles that showed a strong similarity to those of the environmental strains, while others had a wider genetic distance from both environmental strains and clinical strains from other patients. This may suggest not only the occurrence of multiple independent infections possibly from multiple sources, but also a genetic drift for yeasts once their living environments change from birds to human patients, as suggested by several studies [50, 51] . Additional environmental sampling from broader areas of Ivory Coast might clarify the potential link between clinical and environmental genotypes. Extensive environmental sampling in and around patients' households is needed to investigate the hypothesis of local acquisition of Cryptococcus.
In conclusion, our results here describe the detailed ecological and clinical population genetic analyses of Cryptococcus isolates in Abidjan, Ivory Coast. These results support our previous observations that C. neoformans (A, AFLP1/VNI) is widespread in the environment and is also associated with the most cases of cryptococcosis. This study also confirms that some patients can be infected by different sero-genotypes at once. It is thus important to promote the detection of mixed infections by analysing different isolates instead of a single isolate for each clinical sample. Finally, we have suggested a possible genetic relationship and noted a possible source of contamination from the environment to the patients. To confirm these findings, future studies will be performed by gathering environmental samples directly at patients' homes, gardens or poultry cages.
Funding information
The authors received no specific grant from any funding agency.
